Department of Medical and Paediatric Oncology, GCRI, Ahmedabad, Gujarat, India.
Department of Medical Oncology, GCRI, Ahmedabad, Gujarat, India.
Indian J Pharmacol. 2018 Sep-Oct;50(5):284-286. doi: 10.4103/ijp.IJP_547_17.
Hand-foot syndrome (HFS) is a relatively frequent adverse reaction to certain anticancer drugs. HFS is a type of dermatitis which has been most commonly described with 5-fluorouracil and capecitabine. However, HFS with paclitaxel is rare and has been reported sparingly in the literature. A 52-year-old male patient with recurrent carcinoma of the buccal mucosa was started on palliative chemotherapy regimen, injection paclitaxel (175 mg/m) in combination with injection carboplatin. On post-chemotherapy day 13, the patient started developing pain, dysesthesia followed by bullae formation, and desquamation over palms and soles. Clinically, the patient had Grade 3 HFS characterized by symmetrical, tender skin lesions over the dorsal aspect of palms, and soles with desquamation necessitating interruption of treatment. Therefore, this case has been presented to be cognizant with this rare form of side effect with one of the most commonly used drug in oncology.
手足综合征(HFS)是某些抗癌药物相对常见的不良反应。HFS 是一种皮炎,最常与氟尿嘧啶和卡培他滨一起描述。然而,紫杉醇引起的 HFS 很少见,文献中也很少有报道。一名 52 岁男性复发性颊黏膜癌患者开始接受姑息性化疗方案,注射紫杉醇(175mg/m)联合注射卡铂。化疗后第 13 天,患者开始出现疼痛、感觉异常,随后出现水疱形成和手掌和脚底脱皮。临床上,患者出现 3 级 HFS,表现为手掌和脚底背部对称、压痛性皮肤损伤,伴有脱皮,需要中断治疗。因此,提出了这种罕见形式的副作用病例,这是肿瘤科最常用药物之一。